Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 894999 |
Synonyms | |
Therapy Description |
BI 894999 is a bromodomain (BET) inhibitor with selective activity against BRD2/3/4 and BRDT, which may result in G1 arrest and apoptosis, and inhibition of tumor growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B79, PMID: 29491412). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 894999 | BI894999|BI-894999 | BET Inhibitor (Pan) 32 | BI 894999 is a bromodomain (BET) inhibitor with selective activity against BRD2/3/4 and BRDT, which may result in G1 arrest and apoptosis, and inhibition of tumor growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B79, PMID: 29491412). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |